Send a Tweet
Most Popular Choices
Share on Facebook 31 Share on Twitter Printer Friendly Page More Sharing
Life Arts    H3'ed 11/29/21

Beware of These Drug Maker Tricks

By       (Page 1 of 2 pages)   1 comment
Message Martha Rosenberg
Become a Fan
  (84 fans)

Used by permission from Dreamstime
Used by permission from Dreamstime
(Image by Dreamstime)
  Details   DMCA
>

I have often reported on the drug maker ruse of "disease mongering" or "selling sickness"-- floating symptoms of scary diseases that you may have right now with convenient online, "symptom quizzes" for you to self-diagnose and verify. Long gone are the days when the medical establishment assured you that you were well ("take two aspirins and call me in the morning") thanks to direct-to-consumer advertising.

Disease mongering makes patients into de facto drug reps who tell the doctor both the condition they have and the exact med they need--it makes a mockery of medical school education. A current example of disease mongering is AbbVie's promotion of the obscure-to-barely-existent condition of "exocrine pancreatic insufficiency" whose ads include voices brazenly leading the witness (or patient) by asking "Could I have EPI?"

Another insidious drug maker ruse, seen currently, is the marketing push for "early treatment." If you suspect you have an advertised disease (we hope) don't wait--treat it now! (Before the symptoms go away says one of my doctor colleagues.)

But, whether for ADHD, asthma, mental conditions, "osteopenia," cholesterol risks, pre-diabetes or autoimmune conditions, early treatment disallows a patient to find a natural/lifestyle treatment or "outgrow" a condition if they are a child. Instead early treatment creates lifelong drug customers who will never know if they ever even needed a med.

At an America Psychiatric Association annual meeting I attended, a doctor who directed outpatient psychiatry at Rhode Island Hospital suggested that precisely becausemental illnesses can be lifelong, a wait and see approach should be adopted rather than early treatment. (He also noted a correlation between unconfirmed and over-diagnosed cases of bipolar disorder and disability payments.)

A few weeks ago, Janssen Scientific Affairs (part of Johnson and Johnson) announced that according to its own data, "early initiation of long-acting injectable antipsychotics (LAIs) was associated with fewer inpatient stays" and emergency room visits in Medicaid patients with schizophrenia. Though a drug maker saying its own drug works on the basis of its own research is essentially an ad, medical media are treating it like news.

By citing fewer inpatient stays and ER visits, Janssen implies that early treatment lowers medical costs but its recently FDA-approved LAI, called INVEGA HAFYERA├ "× which costs between $11,760.28 and $17,640.05 (not a typo) shows it is really just cost shifting--to Janssen.

Private health insurers won't pay such prices so it is no wonder Janssen wants to heist Medicaid and government program dollars. Hepatitis C drug makers (whose meds cost $84,000 for 12 weeks) also looted Medicaid, almost bankrupting some states.

Next Page  1  |  2

(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).

Rate It | View Ratings

Martha Rosenberg Social Media Pages: Facebook page url on login Profile not filled in       Twitter page url on login Profile not filled in       Linkedin page url on login Profile not filled in       Instagram page url on login Profile not filled in

Martha Rosenberg is an award-winning investigative public health reporter who covers the food, drug and gun industries. Her first book, Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health, is distributed by Random (more...)
 

Go To Commenting
The views expressed herein are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.
Writers Guidelines

 
Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
Support OpEdNews

OpEdNews depends upon can't survive without your help.

If you value this article and the work of OpEdNews, please either Donate or Purchase a premium membership.

STAY IN THE KNOW
If you've enjoyed this, sign up for our daily or weekly newsletter to get lots of great progressive content.
Daily Weekly     OpEd News Newsletter
Name
Email
   (Opens new browser window)
 

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

Grassley Investigates Lilly/WebMD link Reported by Washington Post

The Drug Store in Your Tap Water

It's the Cymbalta Stupid

Are You Sure You're Not Psychotic Asks Shameless Drug Company?

Another Poorly Regulated "Derivative"--the Antidepressant Pristiq

MRSA and More. Antibiotics Linked to Obesity and Allergies, Too

To View Comments or Join the Conversation:

Tell A Friend